Cover Image
市場調查報告書

GenSight Biologics SA- 產品平台檢討

GenSight Biologics SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 330580
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
GenSight Biologics SA- 產品平台檢討 GenSight Biologics SA - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 21 Pages
簡介

GenSight Biologics SA是總公司設在法國的生物製藥企業。著重以基因治療為基礎的醫藥品的開發及商品化。開發視網膜退化性疾病,及遺傳性原因的低視力,維持、回復視覺障礙患者的視力的解決方案。

本報告提供GenSight Biologics SA的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

GenSight Biologics SA的基本資料

  • GenSight Biologics SA概要
  • 主要資訊
  • 企業資料

GenSight Biologics SA:R&D概要

  • 主要的治療範圍

GenSight Biologics SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

GenSight Biologics SA:開發中產品概況

  • 在臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段處於的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

GenSight Biologics SA:藥物簡介

  • GS-010
  • Gene Therapy for Choroideremia
  • GS-020
  • Gene Therapy for Usher 1A

GenSight Biologics SA:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

GenSight Biologics SA:最近的開發平台資訊

GenSight Biologics SA:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06925CDB

Summary

Global Markets Direct's, 'GenSight Biologics SA - Product Pipeline Review - 2015', provides an overview of the GenSight Biologics's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GenSight Biologics's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GenSight Biologics SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GenSight Biologics SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GenSight Biologics SA's pipeline products

Reasons to buy

  • Evaluate GenSight Biologics SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GenSight Biologics SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GenSight Biologics SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GenSight Biologics SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GenSight Biologics SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GenSight Biologics SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GenSight Biologics SA Snapshot
    • GenSight Biologics SA Overview
    • Key Information
    • Key Facts
  • GenSight Biologics SA - Research and Development Overview
    • Key Therapeutic Areas
  • GenSight Biologics SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • GenSight Biologics SA - Pipeline Products Glance
    • GenSight Biologics SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • GenSight Biologics SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • GenSight Biologics SA - Drug Profiles
    • GS-010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Choroideremia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Usher 1A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GenSight Biologics SA - Pipeline Analysis
    • GenSight Biologics SA - Pipeline Products by Route of Administration
    • GenSight Biologics SA - Pipeline Products by Molecule Type
  • GenSight Biologics SA - Recent Pipeline Updates
  • GenSight Biologics SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GenSight Biologics SA, Key Information
  • GenSight Biologics SA, Key Facts
  • GenSight Biologics SA - Pipeline by Indication, 2015
  • GenSight Biologics SA - Pipeline by Stage of Development, 2015
  • GenSight Biologics SA - Monotherapy Products in Pipeline, 2015
  • GenSight Biologics SA - Phase I, 2015
  • GenSight Biologics SA - Preclinical, 2015
  • GenSight Biologics SA - Discovery, 2015
  • GenSight Biologics SA - Pipeline by Route of Administration, 2015
  • GenSight Biologics SA - Pipeline by Molecule Type, 2015
  • GenSight Biologics SA - Recent Pipeline Updates, 2015

List of Figures

  • GenSight Biologics SA - Pipeline by Top 10 Indication, 2015
  • GenSight Biologics SA - Pipeline by Stage of Development, 2015
  • GenSight Biologics SA - Monotherapy Products in Pipeline, 2015
  • GenSight Biologics SA - Pipeline by Top 10 Route of Administration, 2015
  • GenSight Biologics SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top